Kalaris Therapeutics Inc

NASDAQ:KLRS

Biotechnology

Healthcare
$2.30 +3.52%

+$0.16 today

Market cap
$54.75M
Beta
0.14
P/E (TTM)
-2.5
EPS (TTM)
-$1.86
52W Low $2.14High $11.88

Volume 0.07M

Average 0.08M

KLRS Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Kalaris Therapeutics IncNASDAQ: KLRS

Operating Income · Q1 FY2026 · quarter ended Mar 2026

Operating income remains negative

Q1 FY2026 operating income was -$11.83M, compared with -$10.35M a year earlier. Trailing-twelve-month operating income was -$47.63M.

Context

  • Operating income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether operating income reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the +16.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$11.83M-9.6% QoQ
Last fiscal yearDec 2025
-$46.15M+16.5% YoY
LTMMar 2026
-$47.63M+33.8% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-14.3%+100.0%+114.3 pp
1 year+16.5%+100.0%+83.5 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(46.15M) USD
Year-over-year change
+16.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How KLRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +33.8% is the 2nd highest of 9, against a peer median of +3.9%.
KLRS Competitors
Operating Income for KLRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IFRXInflaRx N.V.LTM Mar 2026-€42.37M EUR+20.8%—144445.0%
CNTXContext Therapeutics Inc.LTM Mar 2026-$43.52M USD-37.6%——
KLRSKalaris Therapeutics IncLTM Mar 2026-$47.63M USD+33.8%——
OVIDOvid Therapeutics Inc.LTM Mar 2026-$47.74M USD+16.3%—670.2%
STTKShattuck Labs, Inc.LTM Mar 2026-$52.66M USD+29.7%—5266.4%
IMAImageneBio IncLTM Mar 2026-$55.93M USD-8.5%——
CNTBConnect Biopharma Holdings LimitedFY2025-$58.07M USD-158.7%—90740.6%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026-$92.07M USD-22.8%——
STROSutro Biopharma, Inc.LTM Mar 2026-$115.08M USD+54.0%—115.5%
Peer median (excluding KLRS) —+3.9%—5266.4%

Competitors are the stored peer set for KLRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue1.12M00013K
Gross Profit(1.12M)000(13K)
Gross Margin—————
Research & Development119.62M11.76M11.71M12.34M30.75M
Selling, General & Admin49.08M2.24M1.76M42.92M15.39M
Operating Expenses168.7M14.01M13.46M55.26M46.14M
Depreciation & Amortization1.12M00013K
EBITDA(169.84M)(15.25M)(14.01M)(58.77M)(41.98M)
EBITDA Margin—————
Operating Income(169.82M)(14.01M)(13.46M)(55.26M)(46.15M)
Operating Margin—————
Interest Income1.32M005.49M0
Interest Expense0235K687K01.44M
Other Income / Expenses(1.14M)(1.48M)(1.24M)(3.51M)2.71M
Income Before Tax(170.96M)(15.49M)(14.7M)(58.77M)(43.44M)
Pre-Tax Margin—————
Income Tax Expense1.01M0000
Net Income(171.96M)(15.49M)(14.7M)(58.77M)(43.44M)
Net Margin—————
EPS (Basic)(63.00)(50.62)(42.09)(11.73)(2.85)
EPS (Diluted)(63.00)(50.62)(42.09)(11.73)(2.85)
Weighted Avg Shares2.73M3.33M4.52M5.01M15.27M
Weighted Avg Shares (Diluted)2.73M3.33M4.52M5.01M15.27M

Kalaris Therapeutics Inc

NASDAQ:KLRS

Intrinsic Alpha fair value

Locked

Current Price

$2.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.